Medicsight PLC (AIM: MDST), industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which assists in the early detection and diagnosis of disease, announces a new global partnership with Ziosoft Inc ("Ziosoft"), a leading developer of 3D advanced visualization and analysis technology. Combined Ziosoft-Medicsight products for the detection of colorectal polyps will be distributed through the Ziosoft network.

Both companies are presenting at the 94th Scientific Assembly and Annual Meeting of the Radiological Society of North America, which is being held in Chicago, 30 November until 5 December 2008. The companies are demonstrating the first results of the partnership at the Ziosoft booth (#7957).

Ziosoft is a market leader for 3D workstations. In 2007 the company had an install base of more than 1,500 3D systems. The companies are working together to integrate Medicsight's ColonCAD with Ziosoft's Ziostation, and the product is due for global launch early in 2009. US launch will follow the product's US FDA clearance, also expected in early 2009.

David Sumner, Chief Executive of Medicsight, said: "The partnership with Ziosoft is part of our ongoing strategy to build a broad base distribution channel, which will enable us to quickly penetrate global markets. Global demand for CT colonography looks set to increase dramatically, with clinical evidence such as the recently published US National CT Colonography Trial (ACRIN 6664) demonstrating the positive benefits of CTC as a screening procedure for the early detection of colorectal cancer".

"This is the ideal time for Ziosoft to partner with Medicsight." said Mark Koeniguer, COO of Ziosoft. "There is great demand from the radiology community for intelligent software that will increase their productivity. The partnership will enable us to combine our revolutionary 3D imaging applications with the CAD and image analysis solutions of Medicsight to fulfil our Company's goal, which is to meet the needs of any hospital."

For further information:
Medicsight plc
David Sumner
+44 (0)20 7605 7950
www.medicsight.com

Nomura Code
Jonathan Senior
+44 (0) 20 7776 1219
Juliet Thompson
+44 (0) 20 7776 1204

Media enquiries:

Abchurch
+44 (0) 20 7398 7700
Heather Salmond
Stephanie Cuthbert
+44 (0) 20 7398 7718
Simone Alves
+44 (0) 20 7398 7728
stephanie.cuthbert@abchurch-group.com
www.abchurch-group.com

About Medicsight

Medicsight PLC is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's CAD software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data. Medicsight's ColonCAD^™ and LungCAD^™ software products are seamlessly integrated with the advanced 3D visualisation workstations of several industry-leading imaging equipment partners.

About Ziosoft Inc.
Ziosoft, Inc. is a recognised leader in networked advanced visualization and analysis software to benefit physicians, patients, and healthcare specialists. Ziosoft is dedicated to providing intelligent and intuitive clinical tools across the enterprise. Ziosoft is a privately held company with locations in Redwood City, CA and Tokyo, Japan. For more information, visit http://www.ziosoftinc.com.

About Computer-Aided Detection
With increasingly sophisticated radiological imaging hardware such as Multi-Detector CT scanners, radiologists are facing a growing challenge in the amount of detailed patient image data that they must review for each patient examination. Some CT scan examinations generate as many as 2000 images per patient. Review of this data by the radiologist is not only time-consuming but also prone to error due to reader fatigue. CAD software can help the reviewing radiologist by analysing the image data and automatically highlighting suspicious regions of interest for closer inspection. Without CAD software some potential abnormalities or areas of disease may be overlooked. This can be critical for diagnosis and the management of patient outcomes as early detection of disease greatly increases the probability of successful treatment and a positive therapeutic outcome. In addition to supporting individual radiologists CAD also has the potential to help standardise CT interpretation across both individuals and institutions thereby supporting population based screening programmes.

About Medicsight's CAD software
Medicsight's ColonCAD^™ and LungCAD^™ software use an advanced CAD algorithm to analyse CT scans of the colon and lung and automatically highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such as small lesions or regions that are hidden from view behind folds in the colon or normal structures and surrounding tissue in the lung.

Both CAD products seamlessly integrate with the advanced 3D visualisation platforms of industry-leading imaging equipment partners. The integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease. This allows clinical end users to perform either a 'second read', where CAD findings are displayed to the user after completion of an initial review of the CT scan data, or a 'concurrent read' where CAD findings are displayed during the user's initial review of the original CT scan images.

Since inception, Medicsight has developed close and lasting relationships with some of the world's foremost clinicians in product related areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product development. Medicsight also collaborates with a number of leading academic institutions and clinical research programmes worldwide to develop the Company's comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight's products to be validated to the highest possible standards.